Speaker(s): 

Alyson Floyd, MS,CGC, Genetic Counselor II, Geisinger, has nothing to disclose

Brian C. Jameson, DO, Division Chief-Endocrinology, Geisinger, has nothing to disclose

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

1. Describe clinical features and risks associated with hereditary paragangliomas and pheochromocytomas (PGL-PCC) 
2. Review hereditary PGL-PCC case examples from the MyCode GSC cohort
3. Discuss hereditary PGL-PCC surveillance and management recommendations

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Juliann Savatt, MS, LCGC, Melissa Kelly, MS, LCGC, Marc Williams, MD, and Cara McCormick, MPH have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None